Six-month stability of bevacizumab (Avastin) binding to vascular endothelial growth factor after withdrawal into a syringe and refrigeration or freezing
Purpose:To determine the change in anti–vascular endothelial growth factor (VEGF) activity of bevacizumab (Avastin, Genentech, Inc., San Francisco, CA) after refrigeration or freezing.Methods:Samples of bevacizumab were drawn up from new vials into plastic tuberculin syringes and refrigerated at 4°C
Purpose To report the short-term safety, biologic effect, and a possible mechanism of action of intravitreal bevacizumab in patients with neovascular age-related macular degeneration (AMD). Design Interventional, consecutive, retrospective case series. Participants Eighty-one eyes of 79 patients with subfoveal neovascular AMD. Methods Patients received intravitreal bevacizumab (1.25 mg) on a monthly basis until macular edema, subretinal fluid (SRF), and/or pigment epithelial detachment (PED) res...
Abstract To determine whether intravitreal bevacizumab could improve optical coherence tomography and visual acuity outcomes in a patient with neovascular age-related macular degeneration who was responding poorly to pegaptanib therapy, an intravitreal injection of bevacizumab (1.0 mg) was given. Within 1 week, optical coherence tomography revealed resolution of the subretinal fluid, resulting in a normal-appearing macular contour. The improved macular appearance was maintained for at least 4 we...
: To determine whether bevacizumab could improve visual acuity and optical coherence tomography outcomes in a patient with macular edema from central retinal vein occlusion, an intravitreal injection of bevacizumab (1.0 mg) was given. Prior intravitreal injections of triamcinolone acetonide resulted in vision improvement but worsening cataract and borderline glaucoma. Within 1 week of the bevacizumab injection, visual acuity improved from 20/200 to 20/50 and optical coherence tomography revealed...
Abstract Intravitreal injections have become the most commonly performed intraocular treatments worldwide. Because intravitreal injections may induce severe adverse events, such as infectious and noninfectious endophthalmitis, cataract, ocular hypertension, vitreous hemorrhage, or retinal detachment, appropriate awareness of the materials and techniques used are essential to reduce these sight-threatening complications. This review provides insights into the needles, syringes, silicone oil coati...
Resumen Objetivo Analizar las caracteristicas clinicas, el manejo y los resultados de los pacientes con endoftalmitis esteril asociada con el factor de crecimiento endotelial antivascular intravitreo. Metodos Serie de casos de observacion retrospectiva de pacientes con endoftalmitis esteril despues de inyecciones intravitreas anti-VEGF. Se han revisado los datos clinicos de pacientes tratados con anti-VEGF intravitreos durante un ano. Se analizan los que han presentado un episodio de endoftalmit...
Resumen Objetivo Analizar las caracteristicas clinicas, el manejo y los resultados de los pacientes con endoftalmitis esteril asociada con el factor de crecimiento endotelial antivascular intravitreo. Metodos Serie de casos de observacion retrospectiva de pacientes con endoftalmitis esteril despues de inyecciones intravitreas anti-VEGF. Se han revisado los datos clinicos de pacientes tratados con anti-VEGF intravitreos durante un ano. Se analizan los que han presentado un episodio de endoftalmit...
IntroductionPembrolizumab is an anti-PD-1 monoclonal antibody, approved and under development for numerous indications in oncology. It is available as either lyophilized powder for reconstitution o...
Purpose. To compare the outcomes of trabeculectomy using two different routes of bevacizumab administration as an adjunct in patients with primary open angle glaucoma. Methods. Prospective, randomized, masked trial that included 180 eyes of 180 patients of documented primary open angle glaucoma were eligible for surgery. Patients were randomized to receive either a single intraoperative dose of subconjunctival bevacizumab (1.25 mg, Group I) or topical bevacizumab (5 mg/ml) for 30 days (Group II)...
Abstract Vascular endothelial growth factor (VEGF) is a key regulator of abnormal blood vessel growth. As such, bevacizumab-based inhibition of VEGF has been the clinically adapted strategy to treat colorectal and breast cancers as well as age-related macular degeneration (AMD). However, as the treatment of vascular diseases often requires a high drug concentration for a long period, the burst release of bevacizumab remains a critical limitation in anti-VEGF-based therapies. Maintaining bevacizu...
Last. Valérie Sautou(CNRS: Centre national de la recherche scientifique)H-Index: 15
view all 5 authors...
Abstract Monoclonal antibodies (mAbs) are subject to instability issues linked to their protein nature. In this work, we review the different mechanisms that can be linked to monoclonal antibodies instability, the parameters, and conditions affecting their stability (protein structure and concentration, temperature, interfaces, light exposure, excipients and contaminants, and agitation) and the different analytical methods used for appropriate physicochemical stability studies: physical stabilit...
Chorioretinal vascular conditions are among the leading causes of blindness throughout the developed world. Patients usually lose vision because of breakdown of the blood-retinal barrier or complications of neovascularization, two consequences of angiogenesis. These pathophysiologic processes are driven by chemokines and cytokines (particularly vascular endothelial growth factor (VEGF)), which are upregulated by vascular and inflammatory damage to fragile tissues. For the past 15 years, the pref...
Intravitreal injections of antibody-based biologics targeting vascular endothelial growth factor (VEGF) are highly effective and have markedly decreased the risk of visual impairment associated with prevalent retinal diseases, such as neovascular age-related macular degeneration and diabetes macular oedema. The diseases are chronic in their nature, and most patients need long-term therapy to suppress disease activity. We previously reported a compounding method for repackaging and storage of afl...
Purpose:To determine whether sterile preloading of anti–vascular endothelial growth factor agents reduces the risk of postintravitreal injection endophthalmitis.Methods:This is a retrospective cohort study using medical claims data from a large, national US insurer. Cohorts were created using intrav